Latest Conference Articles

Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues and achalasia in patients.

New research identifies CD8+ PD-1+ TIM-3– LAG-3– TILs as promising biomarkers for improved outcomes in metastatic clear cell renal cell carcinoma treatments.

Dr. Michael Soulen discusses safety concerns and adverse events in neuroendocrine tumor treatments, highlighting cytopenia and radiation risks while ensuring patient safety.

The DISCUS trial reveals that shorter systemic therapy improves quality of life for advanced urothelial cancer patients, challenging traditional treatment durations.

Nivolumab combined with visugromab demonstrates enhanced efficacy and tolerability in treating muscle-invasive bladder cancer, outperforming placebo in a recent trial.

A novel treatment combining chemotherapy and PRRT shows promising safety and efficacy for neuroendocrine tumors, with high response rates and ongoing trials.

Neoadjuvant gemcitabine plus cetrelimab shows promising pCR and RFS rates in muscle-invasive bladder cancer, highlighting new treatment options.

Lutetium Lu 177 vipivotide tetraxetan significantly enhances survival in metastatic hormone-sensitive prostate cancer when combined with standard therapies, according to recent trial results.

A novel combination therapy shows promise for preserving kidneys in high-risk upper tract urothelial carcinoma, challenging traditional treatment methods.

Experts explore a novel combined therapy for liver-dominant neuroendocrine tumors, enhancing treatment durability with chemotherapy and PRRT.

Dr. Jonathan Strosberg discusses the promising results of the ALPHAMEDIX-02 trial, evaluating a new therapy for advanced neuroendocrine tumors.

Novel approaches in MDS focus on HMA doublets, but transplant remains the only curative option to date.

Vivek Subbiah emphasizes tumor-agnostic therapies' potential to revolutionize cancer treatment by targeting genetic biomarkers, ensuring equitable access to precision medicine.

Experts discuss the importance of collaboration in improving surgical standards and treatment outcomes for neuroendocrine tumors through the CUTNETs initiative.

Healthcare professionals adjust octreotide and lanreotide doses for effective symptom control in patients with carcinoid syndrome, following NCCN guidelines.

Mary Maluccio, MD, MPH, FACS, discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 trial and ongoing patient follow-up.

Dr Mary Maluccio discusses promising results and safety concerns from the ALPHAMEDIX-02 trial on innovative therapy for GEP-NETs.

New trial results reveal ITM-11 significantly improves survival rates in GEP-NET patients, outperforming everolimus with better efficacy and safety profiles.

A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell carcinoma, despite higher toxicity risks.

Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns and the need for further research.

Explore the latest insights on somatostatin analogs, dose adjustments, and emerging treatments for managing carcinoid syndrome symptoms effectively.

Experts discuss the CUTNETs collaborative's efforts to enhance surgical care and standardize treatment for neuroendocrine tumors across multiple centers.

AI transforms healthcare by personalizing treatment plans and enhancing patient-provider communication, revolutionizing how we approach medical care.

AI transforms cancer treatment by personalizing care and enhancing patient-provider communication, revolutionizing how patients manage their health.

A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving the way for future trials.

The identification of biomarkers in frontline diffuse large B-cell lymphoma (DLBCL) is ramping up with interest in exploring cell of origin.

Experts discuss the impact of dose escalation in treating neuroendocrine tumors, highlighting recent trials and collaborative research efforts for improved patient outcomes.

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.

Rising early-onset neuroendocrine tumors reveal unique challenges and disparities, highlighting the need for tailored care and research focused on younger patients.